Related Experiment Videos
Growth hormone treatment and pseudotumor cerebri: coincidence or close relationship?
Grafton D Reeves1, Daniel A Doyle
1Division of Endocrinology, Alfred I. duPont Hospital for Children, Wilmington, DE 19899, USA. greeves@nemours.org
Insights
Pseudotumor cerebri (PTC), a serious condition causing vision loss, is linked to recombinant human growth hormone (GH) therapy in children. This study analyzes data to understand this association and guide future recommendations.
Area of Science:
- Pediatric Endocrinology
- Neuro-ophthalmology
- Pharmacovigilance
Background:
- Pseudotumor cerebri (PTC) is an uncommon but serious condition in children, potentially leading to irreversible vision loss.
- Recombinant human growth hormone (GH) therapy has emerged as a recently recognized risk factor for pediatric PTC.
- Understanding the association between GH therapy and PTC is crucial for patient safety and effective management.
Purpose of the Study:
- To analyze data from the National Cooperative Growth Study (NCGS) to investigate the relationship between recombinant human GH therapy and PTC in pediatric patients.
- To evaluate the plausibility and probability of GH therapy as a risk factor for PTC.
- To provide a comprehensive overview of PTC in the context of GH therapy, including clinical presentations, management, and outcomes.
Main Methods:
- Analysis of postmarketing surveillance data from Genentech's National Cooperative Growth Study (NCGS).
- Examination of clinical and laboratory data to assess the association between GH therapy and PTC.
- Review of existing knowledge regarding PTC and GH therapy.
Main Results:
- The study examines the association between recombinant human GH therapy and the occurrence of PTC in a pediatric cohort.
- Data analysis focuses on the plausibility, probability, and clinical characteristics of PTC in patients receiving GH therapy.
- The findings contribute to understanding the risk profile associated with GH treatment in children.
Conclusions:
- Recombinant human GH therapy is a potential risk factor for pseudotumor cerebri in the pediatric population.
- Further research and vigilance are recommended to fully elucidate the relationship and ensure patient safety.
- This analysis provides essential insights for clinicians managing pediatric patients undergoing GH therapy.
Abstract:
Pseudotumor cerebri (PTC) is an uncommon disorder in the pediatric population. It is not a benign condition. It can cause permanent vision loss. The most recently recognized risk factor for this disorder is recombinant human growth hormone (GH) therapy. Data from Genentech's National Cooperative Growth Study (NCGS), a postmarketing surveillance program, are analyzed to examine the relationship between GH therapy and PTC. Several areas are addressed, including plausibility, probability, clinical and laboratory presentations, management, clinical outcome, present state of knowledge, and future recommendations.